BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
3.990
-0.080 (-1.97%)
May 13, 2025, 4:00 PM - Market closed

BioAge Labs Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-71.05-71.11-63.85-39.72
Depreciation & Amortization
0.170.170.160.13
Loss (Gain) From Sale of Assets
0.060.06--
Stock-Based Compensation
9.086.983.022.54
Other Operating Activities
0.191.2116.60.08
Change in Accounts Payable
1.690.01-0.390.99
Change in Unearned Revenue
8.19.193.31-
Change in Other Net Operating Assets
-1.081.983.79-0.2
Operating Cash Flow
-53.21-51.52-37.36-36.18
Capital Expenditures
-0.79-0.37-0.17-0.1
Investment in Securities
-77.56--0.1-
Investing Cash Flow
-78.35-0.37-0.27-0.1
Short-Term Debt Issued
--23.5-
Long-Term Debt Issued
--12.52.5
Total Debt Issued
--362.5
Long-Term Debt Repaid
--6-1-
Net Debt Issued (Repaid)
-6-6352.5
Issuance of Common Stock
222.25222.2500.04
Other Financing Activities
-4.55-5.05-0.06-0.05
Financing Cash Flow
211.7381.234.942.5
Foreign Exchange Rate Adjustments
0.050.08-0.25
Net Cash Flow
80.18329.39-2.69-33.54
Free Cash Flow
-54.01-51.89-37.53-36.28
Free Cash Flow Per Share
-2.80-4.84-22.43-21.70
Cash Interest Paid
1.211.421.160.13
Levered Free Cash Flow
-34.86-34.21-27.91-
Unlevered Free Cash Flow
-33.98-32.73-23.04-
Change in Net Working Capital
-8.71-9.36-4.2-
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q